Share this article on:

Incidence of Hepatocellular Carcinoma in HIV-Infected Patients With Cirrhosis: A Prospective Study

Montes Ramírez, María Luisa MD*; Miró, José M. MD; Quereda, Carmen MD; Jou, Antoni MD§; von Wichmann, Miguel Ángel MD; Berenguer, Juan MD; González-García, Juan J. MD*; Hernando, Asunción MD#; Ortega, Enrique MD**; Sanz, José MD††; Arribas, José R. MD*GESIDA 3703.FIPSE 36466503–N5 NEAT Study Group

JAIDS Journal of Acquired Immune Deficiency Syndromes: January 1st, 2014 - Volume 65 - Issue 1 - p 82–86
doi: 10.1097/QAI.0b013e3182a685dc
Brief Report: Clinical Science

Abstract: This study assesses the incidence of hepatocellular carcinoma (HCC) in a prospective cohort of HIV-infected patients, the majority receiving antiretroviral therapy, with liver cirrhosis from different etiologies, enrolled between 2004 and 2005 with median follow-up of 5 years. We followed 371 patients, 25.6% with decompensated cirrhosis at baseline. The incidence rate of HCC was 6.72 per 1000 person-years [95% confidence interval (CI): 2.6 to 10.9]. There was a trend toward a higher cumulative probability of developing HCC at 6 years of follow-up (considering death and liver transplant as competing risks) in patients with decompensated versus compensated cirrhosis at baseline (6% vs. 2%, P < 0.06).

*HIV Unit, Service of Internal Medicine, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain;

Service of Infectious Diseases, Hospital Clínic/IDIBAPS, University of Barcelona, Barcelona, Spain;

Service of Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain;

§HIV Clinical Unit, Internal Medicine Department and Fundació de la Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain;

Unit of Infectious Diseases, Hospital Donostia, Donostia-San Sebastián, Spain;

Infectious Diseases and HIV Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain;

#HIV Unit, Hospital 12 de Octubre and Universidad Europea de Madrid, Madrid, Spain;

**Unit of Infectious Diseases, Hospital General Universitario de Valencia, Valencia, Spain; and

††Service of Internal Medicine, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

Correspondence to: María Luisa Montes Ramírez, MD, Consulta de Medicina Interna 2, Hospital Universitario La Paz, Paseo de la Castellana 261, E-28046 Madrid, Spain (e-mail:

J.R.A. is an investigator for Programa de Intensificación de la Actividad Investigadora en el SNS (I3SNS); IdiPAZ AIDS and Infectious Diseases Investigator Group is partially supported by “Red de Investigación en SIDA” (AIDS Research Network) (RIS) RD07/0006/2007, GESIDA 37/03.FIPSE 364665/03 and N5 NEAT Study Group.

The authors have no conflicts of interest to disclose.

The GESIDA 37/03.FIPSE 364665/03–N5 NEAT Study Group Investigators are listed in Appendix 1.

Received April 25, 2013

Accepted July 16, 2013

© 2014 by Lippincott Williams & Wilkins